After Januvia And Onglyza, Novartis Launches Galvus In China; Lucentis Receives SFDA Nod

By Jialing Dai, Tamra Sami / Email the Authors / “The Pink Sheet” DAILY Jan. 20, 2012
Word Count: 1505 / Article # 14120120001

Executive Summary

Novartis looks to take on Merck’s Januvia in China, noting it will have a level-playing field despite playing catch up in the market with the world’s largest diabetes population.

Purchase this Article

$85.00 Buy Now

For $85.00, purchase this 1505-word article and receive immediate online access. 100% Satisfaction Guarantee.

View a complete sample article »

Already a Subscriber?

Log in for complete access.

Questions?

Call Toll-Free (800) 332-2181 or +1 (908) 547-2159.

Log In

Email Address

Password

Remember Me

Forgot your password?

Don’t Have an Account?

If your employer has a site license, create your account to begin using it. Simply click ‘Create An Account’ button below to register now.

Otherwise, please explore our free content subscriptions.

Create an account

Enter the email address associated with your account and a temporary password will be sent to you.

Email Address

Need help? Contact us at (800) 332-2181, +1 (908) 547-2159, or custcare@elsevier.com

Email Article

* Required field

* To:

For multiple recipients, separate email addresses with a semi-colon.

* Your Name:

* Your Email:

Subject: After Januvia And Onglyza, Novartis Launches Galvus In China; Lucentis Receives SFDA Nod

* Add a personalized message to your email:

Please Note: Only individuals with subscriptions to “The Pink Sheet” DAILY will be able to access the full article. All other readers will be directed to the abstract and may purchase the article.

or Cancel

After Januvia And Onglyza, Novartis Launches Galvus In China; Lucentis Receives SFDA Nod

Executive Summary

Purchase this Article

Already a Subscriber?

Questions?

Related Articles: 12

Elsevier Business Intelligence Publications

Offers & Events

Topics Covered in this Article

Email Article